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We have been questioned on how we came to suggest that the
cause of increased ferritin levels in patients with Crimean-Congo
hemorrhagic fever (CCHF) is due to hemophagocytic lymphohis-
tiocytosis (HLH) without having done bone marrow aspirations
(BMA) and without observing the erythrocytes, lymphocytes,
neutrophils, or thrombocytes phagocytized by macrophages on
BMA smear. The main aim of our study was to examine ferritin, a
new marker for CCHF, as a diagnostic and prognostic factor; we
found it to be a reliable marker for the severity of infection, i.e.,
increased ferritin levels were associated with severe illness.1 We
also found that ferritin started to increase during the initial days of
admission, before hemorrhage, and 77.3% of patients had increased
ferritin levels.1 Hence it could be used in the diagnosis of CCHF
because the measurement of ferritin is cheap and simple and other
acute phase reactants such as C-reactive protein have been found
to be only slightly elevated in CCHF patients.2
In our study, we discussed and suggested that the increased
ferritin levels may be related to hemophagocytosis, which has
previously been proposed as an underlying mechanism.3,4 Other
than being the major iron storage protein, ferritin is also an acute
phase protein and increases in the presence of acute or chronic
disease conditions. Extremely high ferritin levels are seen in HLH,
histiocytic malignancies, and adult-onset Still’s disease; hence it
has been accepted as one of the diagnostic criteria of HLH.
Cytokines such as interleukin (IL)-1, IL-6, interferon (IFN)-g, and
tumor necrosis factor (TNF), which are implicated in the
pathophysiology of HLH, have been shown to greatly induce
ferritin synthesis.5 These cytokines have also been shown to be
increased in CCHF, and we have seen extremely high ferritin levels
in our CCHF patients.1,6 Thus I suggest that there is a good
correlation between ferritin and the levels of some cytokines that
are especially related to cell-mediated immunity.
Soluble CD25 levels and decreased natural killer cell activity,
which are implicated in HLH, could also be early indicators of
CCHF, as well as high ferritin levels, but tests for these are not
widely available.
The exact pathogenetic mechanism of CCHF and what causes
thrombocytopenia and bleeding in CCHF patients is not clear, and
this ﬁeld remains controversial; HLH, disseminated intravascular
coagulation (DIC), or both of them. Ergonul et al. have found that
CCHF patients with a fatal outcome had higher DIC scores than
non-fatal cases, but they detected elevated D-dimer values in only
53.3% of patients.6 The vast majority of CCHF patients have
thrombocytopenia from the earlier stages of the disease; the cause
of this abnormality might be elevated levels of cytokines such as1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.08.017IFN-g and TNF, which suppress the production of platelets in the
bone marrow, rather than the excess consumption occurring in
DIC. Thus, HLH might be responsible for the clinicopathologic
changes in CCHF. There has been some evidence to support this
suggestion, contradictory to DIC. A recent study showed that there
was a signiﬁcant decrease of thrombin-activatable ﬁbrinolysis
inhibitor activity in CCHF patients, though D-dimer values were
within the normal range in all patients.2 Acrocyanosis secondary to
microcirculation collapse and thromboembolisms that develop
during DIC, especially in the course of Gram-negative sepsis like
meningococcemia, is not seen in CCHF patients. Additionally, there
has been no histological evidence for DIC in CCHF so far. Despite all
these facts, because coagulation abnormalities are frequently seen
in CCHF patients, especially in the later stages of fatal cases, DIC
may have a role in the pathophysiology of CCHF. I speculate that
DIC may occur in some severe cases and may have an additive
effect on the pathology, contributing to a poor prognosis.
In conclusion, ferritin, along with thrombocytopenia, can be
used as a tool for the diagnosis of CCHF, and high levels of ferritin
together with DIC markers and proinﬂammatory cytokines in the
late stages of illness are correlated with a poor prognosis.
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